Clinical Drug Investigation
Papers 2744
1 page of 275 pages (2,744 results)
#1Ramakrishna NirogiH-Index: 18
Last. Satish JettaH-Index: 1
view all 11 authors...
#1Racine Ramnath (UWI: University of the West Indies)
#2M Gossell-Williams (UWI: University of the West Indies)H-Index: 8
#1Juan Antonio García-Carmona (Sofia University)H-Index: 1
#2Jorge Simal-Aguado (University of Murcia)
Last. Alejandro Galindo-Tovar (University of Murcia)H-Index: 5
view all 5 authors...
BACKGROUND AND OBJECTIVE: Long-acting injectable antipsychotics (LAIs) have been widely studied in schizophrenia and evidence suggests that they could be also used for the treatment of bipolar and schizoaffective disorders. Nonetheless, there are no studies evaluating their role in other psychiatric disorders. We aimed to evaluate the use of the newest monthly and 3-monthly LAIs-aripiprazole once monthly, paliperidone 1- and 3-monthly (PP1M, PP3M)-against the 2-weekly LAIs, using the following c...
#1Jesse J. Corry (United Hospital)
#2Ganesh Asaithambi (United Hospital)H-Index: 1
Last. Megan E. Tipps (Abbott Northwestern Hospital)
view all 9 authors...
BACKGROUND: Perihematomal edema (PHE) growth in intracranial hemorrhage (ICH) is a biomarker for worse outcomes. Although the management of PHE is potentially beneficial for ICH patients, there is currently no proven clinical therapy that both reduces PHE and improves outcomes in this population. OBJECTIVE: To examine the safety and tolerability of conivaptan, a non-peptide vasopressin (AVP) receptor antagonist, for the management of PHE in ICH patients. METHODS: We performed a single-center, op...
#1Andrea Cocci (UniFI: University of Florence)H-Index: 8
#2Fabrizio Di Maida (UniFI: University of Florence)H-Index: 2
Last. Marco Falcone (UNITO: University of Turin)H-Index: 9
view all 16 authors...
BACKGROUND AND OBJECTIVE: Plaque formation ordinarily takes place in the acute phase of Peyronie's disease. There is no unanimous consent regarding the management of the acute phase of Peyronie's disease. The objective of this study was to evaluate the advantages of using a single intralesional injection of collagenase Clostridium histolyticum in patients with the active phase of Peyronie's disease and to assess its effect on disease progression by reducing penile curvature and ameliorating pain...
#1Shengyu Zhang (USTC: University of Science and Technology of China)H-Index: 1
#2Lei Li (USTC: University of Science and Technology of China)H-Index: 1
Last. Zhigang Qi (Nanjing Medical University)
view all 5 authors...
Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approv...
#1Tae-Hwan Kim (Hanyang University)H-Index: 29
#2Shin-Seok Lee (Chonnam National University)H-Index: 17
Last. Dae Hyun Yoo (Hanyang University)H-Index: 18
view all 8 authors...
BACKGROUND: The infliximab biosimilar CT-P13 has widely received regulatory approval in all indications of reference infliximab, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). OBJECTIVE: This retrospective analysis investigated drug survival and long-term safety and effectiveness of CT-P13 in patients with RA or AS in the Republic of Korea. METHODS: This non-interventional, retrospective, multicenter analysis collected medical record data for adult patients with RA or AS wh...
#1Kazuya FukumuraH-Index: 5
#2Nao KawaguchiH-Index: 3
Last. Eriko Ogura (CGD: Center for Global Development)
view all 6 authors...
BACKGROUND: Naldemedine is a peripherally acting mu-opioid receptor antagonist that is indicated to treat opioid-induced constipation. OBJECTIVES: To assess the potential for drug-drug interactions between a single oral dose of naldemedine and the oral P-glycoprotein inhibitor cyclosporine, cytochrome P450 (CYP) 3A inhibitors itraconazole and fluconazole, and CYP3A inducer rifampin. METHODS: Three Phase 1, open-label studies were conducted in healthy subjects. In the P-glycoprotein inhibitor stu...
Top fields of study
Diabetes mellitus